Key Points
- David Malcom Rodman sold 7,709 shares of Mineralys on Jan. 13 at an average price of $32.75 for $252,469.75, leaving him with 61,804 shares and marking an 11.09% reduction in his ownership from prior levels.
- Heavy insider selling in early January: Rodman executed multiple sales (Jan. 2, 5, 9, 12, 13, 14) that together total roughly $10.2 million, signaling significant insider liquidation over a short period.
- Stock and analyst context: MLYS is down about 6.1% (opened $31.38) with a $2.48B market cap, while analysts hold a consensus "Moderate Buy" rating and a $47.43 price target.
Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) insider David Malcom Rodman sold 7,709 shares of the company's stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $32.75, for a total transaction of $252,469.75. Following the completion of the sale, the insider directly owned 61,804 shares of the company's stock, valued at approximately $2,024,081. This trade represents a 11.09% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
David Malcom Rodman also recently made the following trade(s):
- On Wednesday, January 14th, David Malcom Rodman sold 11,367 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $32.61, for a total transaction of $370,677.87.
- On Monday, January 12th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $32.32, for a total transaction of $205,167.36.
- On Friday, January 9th, David Malcom Rodman sold 2,170 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $33.27, for a total transaction of $72,195.90.
- On Friday, January 2nd, David Malcom Rodman sold 70,037 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $35.87, for a total value of $2,512,227.19.
- On Monday, January 5th, David Malcom Rodman sold 192,715 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $35.02, for a total transaction of $6,748,879.30.
Mineralys Therapeutics Stock Down 6.1%
Shares of Mineralys Therapeutics stock opened at $31.38 on Friday. The company has a market cap of $2.48 billion, a P/E ratio of -10.64 and a beta of 0.49. The firm's 50 day moving average price is $38.51 and its 200-day moving average price is $30.91. Mineralys Therapeutics, Inc. has a 52-week low of $8.24 and a 52-week high of $47.65.
Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last announced its earnings results on Monday, November 10th. The company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.66) by $0.14. As a group, equities research analysts forecast that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several brokerages have weighed in on MLYS. Stifel Nicolaus raised their price target on Mineralys Therapeutics from $45.00 to $52.00 and gave the stock a "buy" rating in a report on Friday, December 19th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Mineralys Therapeutics in a research report on Wednesday, October 8th. Wells Fargo & Company increased their price objective on Mineralys Therapeutics from $50.00 to $55.00 and gave the company an "overweight" rating in a report on Tuesday, November 11th. Finally, HC Wainwright raised their price objective on Mineralys Therapeutics from $52.00 to $56.00 and gave the stock a "buy" rating in a research note on Wednesday, November 12th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $47.43.
View Our Latest Stock Analysis on Mineralys Therapeutics
Institutional Investors Weigh In On Mineralys Therapeutics
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Farallon Capital Management LLC acquired a new position in shares of Mineralys Therapeutics in the 3rd quarter valued at about $63,442,000. Holocene Advisors LP purchased a new position in Mineralys Therapeutics during the third quarter valued at approximately $45,708,000. RA Capital Management L.P. lifted its holdings in Mineralys Therapeutics by 19.1% in the third quarter. RA Capital Management L.P. now owns 7,323,750 shares of the company's stock valued at $277,717,000 after acquiring an additional 1,176,470 shares during the period. Polar Capital Holdings Plc purchased a new stake in Mineralys Therapeutics in the 3rd quarter worth approximately $40,149,000. Finally, Alliancebernstein L.P. grew its stake in shares of Mineralys Therapeutics by 3,160.1% during the 3rd quarter. Alliancebernstein L.P. now owns 882,415 shares of the company's stock worth $33,461,000 after purchasing an additional 855,348 shares during the period. 84.46% of the stock is owned by institutional investors and hedge funds.
About Mineralys Therapeutics
(
Get Free Report)
Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
